Aktuella utlysningar, vecka 49, 2019
Grants Office tipsar om aktuella utlysningar
Svenska och nordiska anslag
Stöder forskning vid svenska universitet som är relaterad till den mänskliga hjärnans område. Den totala budgeten är SEK 1,8 miljoner.
Closing date: 13 January 2020
Distinguished investigator grants within biotechnology-based synthesis and production – Nordic region - Novo Nordisk Foundation
Support professor-level investigators with demonstrated ability to address major research questions in conducting biotechnology research projects and promote research at a high international level in the Nordic countries. Up to four grants are available, each worth up to DKK 10 million over five years.
Closing date: 21 January 2020
Emerging investigator grants within biotechnology-based synthesis and production – Nordic region Novo Nordisk Foundation
Support emerging investigators to establish their own research groups or strengthen their recently started groups within biotechnology. Up to four grants are available, each worth up to DKK 10 million for up to five years.
Closing date: 21 January 2020
Ascending investigator grants within biotechnology-based synthesis and production – Nordic region Novo Nordisk Foundation
Support ascending investigators with the ability to lead larger studies in the field of biotechnology. Up to four grants are available, each worth up to DKK 10 million for up to five years.
Closing date: 21 January 2020
Supports the establishment of networks to facilitate the development of long-term joint research between Swedish researchers and researchers from São Paulo in Brazil. The grant is worth SEK 75,000 over one year for the Swedish applicant.
Closing date: 28 January 2020
Medel till forsknings- och utvecklingsprojekt – Sveriges Dövas Riksförbunds Testaments- och Donationsstiftelse
Syftar till att förbättra dövas delaktighet i samhället och öka samverkan, närhet och kunskapsförmedling mellan dövrörelsen, institutioner, organisationer och myndigheter som på olika sätt är berörda av arbetet kring dövfrågor.
Closing date: 1 February 2020
Denna tilläggsutlysning prioriterar projekt som belyser behandlingsmetoder som kan minska sjukfrånvaron vid psykisk ohälsa och projekt som stärker individens möjligheter att arbeta med psykisk ohälsa.
Closing date: 3 February 2020
Pain Alliance Europe and Grünenthal Group invite applications for their brain, mind and pain grant. This aims to identify, stimulate and encourage patient-centric and scientifically robust innovation in the domain of chronic pain and neurological disorders. Other aims include:
•stimulating research and access to innovative treatments;
•promoting prevention and self-management approaches;
•working together to improve quality of life for people living with these disabling conditions.
Natural persons and organisations, including patient, educational, non-profit and commercial organisations, based and operating in Europe may apply. The budget is €90,000.
Closing date: 31 December 2019
The Institut de France’s Fondation Lefoulon-Delalande invites nominations for its scientific grand prize. This recognises a scientist who has made important contributions to cardiovascular physiology, biology or medicine. These fields also include developmental biology, genetics, epidemiology and physiology, as well as clinical biology, imaging techniques, therapeutics and the pharmacology of the cardiovascular system.
Members of the Institut de France are not eligible. Application materials must be submitted in English. The prize is worth €600,000.
Closing date: 10 January 2020
The European Association for Cancer Research, under the Pezcoller Foundation, invites nominations for its cancer researcher award. This recognises academic excellence and achievements in the field of cancer research.
Nominees must meet the following criteria:
•have no more than 15 years postdoctoral experience since completing their PhD or equivalent degree;
•be presently employed in a European institution and have a record of employment in Europe of at least five years;
Self-nominations are not accepted. The award is worth €10,000.
Closing date: 6 January 2020
The European Federation of Immunological Societies invites applications for its doctoral prize. This recognises doctoral theses on immunology and allergology, defended in the last three years in European universities and institutions.
Applicants must be members of an EFIS affiliated national society. Two prizes, worth €30,000 each, are available. The winners have the possibility of receiving an extra €50,000 per year for three years to conduct a research project at a European institution.
Closing date: 31 December 2019
Alzheimer's Research UK and the Dementia Consortium invite expressions of interest for their dementia consortium funding. This supports research projects that aim to provide validation of targets for the treatment of dementia or explore the tractability of the target for drug discovery. Promising targets are moved towards the clinic through the successful licence of these projects to industrial partners with the ultimate aim of bringing benefit to patients. Projects must be collaborative in nature, with involvement from the consortium members in devising the final project plan. Projects are sought that focus on novel molecular targets in neurodegenerative diseases,
Projects should provide evidence linking the target to human disease and a strong rationale for target modulation having a therapeutic effect. Scientists at academic institutions worldwide may apply. The lead applicant is expected to have a contract, either fixed term or tenure, which covers the proposed duration of the grant. Grants are typically worth between £100,000 and £250,000 each over two to three years. Up to £500,000 may be awarded in exceptional cases.
Closing date: 29 January 2020
Notice of Intent to Publish a Funding Opportunity Announcement for Research Answers to NCI’s Provocative Questions
The National Cancer Institute (NCI) intends to publish Funding Opportunity Announcements (FOAs) as Request for Applications (RFAs) to solicit applications responding to the new set of 9 Provocative Questions.
The planned issuance of the PQ Initiative includes a new set of 9 PQs, listed below. Each research project proposed in response to these FOAs must be focused on addressing a specific PQ selected from the list. Additional information defining the research scope for responsive projects (the Intent Statement) will be provided in the FOAs and posted at provocativequestions.cancer.gov
- PQ1: What are the underlying causes of the unexplained rising incidence in certain early-onset cancers?
- PQ2: How does intermittent fasting affect cancer incidence, treatment response, or outcome?
- PQ3: How do selective pressures affect cell competition and cooperation during cancer initiation or development?
- PQ4: What mechanisms explain sex differences in cancer incidence, lesion location, or response to therapy?
- PQ5: What strategies can block or reverse the emergence of new cell lineage states induced by cancer treatments?
- PQ6: How can cancer cachexia be reversed?
- PQ7: What methods can be developed to integrate patient-generated health data into electronic health records?
- PQ8: What strategies improve and sustain the coordination of comprehensive healthcare for underserved cancer patients with comorbid conditions?
- PQ9: What methods can be developed to effectively study small or rare populations relevant to cancer research?
Estimated Total Funding Up to $15.0 million in fiscal year 2021.
Expected Number of Awards 30
Estimated Award Ceiling R01 application budgets are not limited but need to reflect the actual needs of the proposed project. R21 application direct costs are limited to $275,000 over a two-year period, with no more than $200,000 in direct costs allowed in any single year.
Estimated Publication Date of Funding Opportunity Announcement: 15 February, 2020
First Estimated Application Due Date: 15 May, 2020
Earliest Estimated Award Date: 1 March, 2021
Earliest Estimated Start Date: 1 April, 2021
Co-infection and Cancer (R01 Clinical Trial Not Allowed):NIH
The purpose of this Funding Opportunity Announcement (FOA) is to enhance mechanistic and epidemiologic investigations addressing the roles of co-infection. Co-infection is defined as the occurrence of infections by two or more infectious (pathogenic or non-pathogenic) agents – either concurrently or sequentially – and includes both acute and chronic infections by viruses, bacteria, parasites, and/or other microorganisms. Preference will be given to investigations of co-infections with known oncogenic agents (excluding human immunodeficiency virus [HIV]) and of co-infections that engender novel opportunities for prevention and treatment.
Deadlines: 6 March, 2020; thereafter, Standard dates apply by 5:00 PM local time of applicant organization.
The US Department of Defense invites applications for its broad agency announcement for extramural biomedical research and development. This aims to identify and develop techniques, knowledge products, and materiel for early intervention in life-threatening injuries, prolonged field care, human performance optimisation and canine medicine. The proposed research must be relevant to active duty service members, veterans, military beneficiaries, or the American public. Applications must address a relevant health problem responsive to one of the research areas of interest, which include:
•damage control resuscitation;
•prolonged field care;
•portable lab assays and diagnostics;
•force health protection and environmental medicine;
•medical simulation and training technologies;
•human performance optimisation;
Funding is worth up to USD 1.5 million per grant, although most grants are worth up to USD 700,000 each. Projects may last up to two years.
Deadlines: rolling until 31 July , 2023.
Funding Opportunity Announcement (FOA): W81XWH-18-S-SOC1
Funding Level: Grants are generally funded at the $5,000 level. The funds are restricted for use during a specified period of time.
Period: Varies according to request.
The objective of this grant is to provide support for scientific meetings, workshops or conferences relevant to AAT Deficiency and the Alpha-1 Foundation’s mission statement.